Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism
Authors:
- 24 July 2020
- book chapter
- Published by Springer Nature
- Vol. 1276, 137-156
Abstract
Plasma levels of cholesterol, especially low-density lipoprotein cholesterol (LDL-C), are positively correlated with the risk of cardiovascular disease. Buildup of LDL in the intima promotes the formation of foam cells and consequently initiates atherosclerosis, one of the main underlying causes of cardiovascular disease. Hepatic LDL receptor (LDLR) is mainly responsible for the clearance of plasma LDL. Mutations in LDLR cause familiar hypercholesterolemia and increase the risk of premature coronary heart disease. Proprotein convertase subtilisin/kexin-type 9 (PCSK9) promotes LDLR degradation and thereby plays a critical role in the regulation of plasma cholesterol metabolism. PCSK9 can bind to LDLR and reroute the receptor to lysosomes for degradation, increasing both circulating LDL-C levels and the risk of cardiovascular disease. PCSK9 is mainly regulated by sterol response element binding protein 2 (SREBP2) at the transcriptional level. Furthermore, many proteins have been identified as interacting with PCSK9, regulating plasma cholesterol levels. Pharmacotherapeutic inhibition of PCSK9 dramatically reduces plasma levels of LDL cholesterol and significantly reduces cardiovascular events. In this article, we summarize the latest advances in PCSK9, mainly focusing on the structure, function, and regulation of the protein, the underlying molecular mechanisms, and its pharmacotherapeutic applications.Keywords
This publication has 154 references indexed in Scilit:
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)PLOS ONE, 2013
- SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretioneLife, 2013
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular MortalityJAMA, 2009
- Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial diseaseAtherosclerosis, 2009
- Switch-like Control of SREBP-2 Transport Triggered by Small Changes in ER Cholesterol: A Delicate BalanceCell Metabolism, 2008
- PCSK9 is required for the disposal of non‐acetylated intermediates of the nascent membrane protein BACE1EMBO Reports, 2008
- Feedback regulation of cholesterol synthesis: sterol-accelerated ubiquitination and degradation of HMG CoA reductaseCell Research, 2008
- Inflammation in atherosclerosisNature, 2002
- Vesicular Tubular Clusters between the ER and Golgi Mediate Concentration of Soluble Secretory Proteins by Exclusion from COPI-Coated VesiclesCell, 1999
- The rate of bulk flow from the endoplasmic reticulum to the cell surfaceCell, 1987